Vontobel Holding Ltd. Has $844,000 Stock Position in Haemonetics Corporation $HAE

Vontobel Holding Ltd. lowered its stake in shares of Haemonetics Corporation (NYSE:HAE) by 28.6% during the 2nd quarter, Holdings Channel.com reports. The firm owned 11,310 shares of the medical instruments supplier’s stock after selling 4,529 shares during the quarter. Vontobel Holding Ltd.’s holdings in Haemonetics were worth $844,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Quarry LP raised its holdings in shares of Haemonetics by 63.4% in the 1st quarter. Quarry LP now owns 495 shares of the medical instruments supplier’s stock worth $31,000 after acquiring an additional 192 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Haemonetics by 59.4% in the 2nd quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier’s stock worth $33,000 after acquiring an additional 165 shares during the last quarter. UMB Bank n.a. raised its holdings in shares of Haemonetics by 91.7% in the 2nd quarter. UMB Bank n.a. now owns 669 shares of the medical instruments supplier’s stock worth $50,000 after acquiring an additional 320 shares during the last quarter. University of Texas Texas AM Investment Management Co. acquired a new stake in shares of Haemonetics in the 1st quarter worth about $65,000. Finally, Strs Ohio acquired a new stake in shares of Haemonetics in the 1st quarter worth about $140,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Weiss Ratings restated a “hold (c-)” rating on shares of Haemonetics in a report on Wednesday, October 8th. Mizuho lowered their target price on shares of Haemonetics from $90.00 to $70.00 and set an “outperform” rating on the stock in a report on Friday, August 8th. Barrington Research restated an “outperform” rating and issued a $86.00 target price on shares of Haemonetics in a report on Tuesday, September 23rd. Citigroup decreased their price objective on shares of Haemonetics from $78.00 to $64.00 and set a “buy” rating for the company in a research note on Tuesday, October 7th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $68.00 price objective (down previously from $84.00) on shares of Haemonetics in a research note on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $75.89.

Haemonetics Stock Down 2.6%

Haemonetics stock opened at $48.86 on Monday. Haemonetics Corporation has a twelve month low of $47.31 and a twelve month high of $94.99. The firm has a 50 day moving average price of $53.66 and a 200-day moving average price of $63.17. The company has a market capitalization of $2.35 billion, a P/E ratio of 14.94, a P/E/G ratio of 0.90 and a beta of 0.37. The company has a quick ratio of 1.04, a current ratio of 1.72 and a debt-to-equity ratio of 1.04.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.10 earnings per share for the quarter, beating analysts’ consensus estimates of $1.01 by $0.09. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. The firm had revenue of $321.39 million during the quarter, compared to the consensus estimate of $305.12 million. During the same period in the prior year, the firm earned $1.02 EPS. The company’s revenue was down 4.4% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. As a group, equities analysts predict that Haemonetics Corporation will post 4.55 EPS for the current year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.